Decree No. 376 / 2011 Coll.
Decree implementing certain provisions of the Public Health Insurance Act
Valid
Order
Effective from 07.12.2011
Contents
ČÁST PRVNÍ
§ 1
§ 2
ČÁST DRUHÁ
HLAVA I
§ 3
§ 4
§ 5
HLAVA II
§ 6
HLAVA III
§ 7
§ 8
HLAVA IV
§ 9
HLAVA V
§ 10
ČÁST TŘETÍ
HLAVA I
§ 11
§ 12
§ 13
§ 13a
§ 13b
HLAVA II
§ 14
HLAVA III
§ 15
HLAVA IV
§ 16
§ 17
ČÁST ČTVRTÁ
HLAVA I
§ 18
§ 19
§ 20
§ 21
HLAVA II
§ 22
§ 23
§ 24
HLAVA III
§ 25
§ 26
§ 27
§ 28
§ 29
§ 30
§ 31
HLAVA IV
§ 32
Díl 1
§ 33
§ 34
Díl 2
§ 35
§ 36
§ 37
§ 38
§ 39
ČÁST PÁTÁ
§ 42
§ 43
ČÁST ŠESTÁ
§ 45
ČÁST SEDMÁ
§ 45b
§ 45c
§ 45d
§ 45e
§ 45f
§ 45g
§ 45h
§ 45i
§ 45j
§ 45k
§ 45l
§ 45m
§ 45n
§ 45o
ČÁST OSMÁ
§ 46
§ 47
Zobrazeno prvních 200 z celkem 443 ustanovení tohoto předpisu.
Zobrazit celý předpis →
Pro stažení celého znění použijte tlačítko Stáhnout výše.
376
DECLARATION
of 1 December 2011
implementing certain provisions of the Public Health Insurance Act
The Ministry of Health provides, pursuant to § 39a (4), § 39b (15), § 39c (11), § 39d (4), § 39f (7), § 39g (4), § 39zc (7), § 39zg (5) and (8) and § 39zi (2) of Act No. 48 / 1997 Coll., on Public Health Insurance and on the amendment and addition of certain related laws, as amended by Act No. 261 / 2007 Coll., Act No. 298 / 2011 Coll. and Act No. 289 / 2025 Coll. (hereinafter "Act '):
INTRODUCTORY PROVISIONS
Subject matter
This decree provides
(a) rules for the selection of the relevant period for the conversion of foreign prices for the medicinal product (the product) and non-categorised foreign-exchange foodstuffs;
(b) the applicable period and rules for establishing the producer's price and assessing the availability of the product and the non-categorised food;
(c) the method of calculating the maximum price of a similar preparation in accordance with § 39a (5) to (7) of the Act;
(d) the rules for the exclusion of the producer's foreign price determined pursuant to Paragraph 39a (2) of the Act from the use for the determination of the maximum price of the product and the rules for the exclusion of the producer's foreign price determined pursuant to Paragraph 39zg (7) from the use for the determination of the maximum price of the non-categorised food;
(e) a tolerance in the number of units of the pharmaceutical form in the packaging of the product ("package size") in the search for the producer's foreign price under § 39a (2) of the Act and a tolerance in the packaging size in the search for the foreign price of the producer of the non-categorised food pursuant to § 39zg (7) of the Act;
(f) rules for increasing the maximum price of the preparation and non-categorised food in the public interest pursuant to Article 17 (2) of the Act;
(g) the rules for the notification of the highest price at which the marketing authorisation holder intends to place the product on the market of a medicinal product, the manufacturer or the importer of a categorised food for special medical purposes or of an unregistered medicinal product used in a specific treatment programme, for products not subject to regulation of the producer price by setting the maximum price;
(h) the rules and limits for increasing or reducing the remuneration against the fixed basic remuneration, taking into account the characteristics of the product under consideration as compared to the other products essentially interchangeable;
(i) the method of calculating the amount of reimbursement of a similar preparation under § 39b (5) to (7) of the Act;
(j) the application of the procedures laid down in Sections 39b to 39i of the Act for the determination or modification of the amount and conditions of reimbursement of products consisting of 2 or more active substances;
(k) the application of the procedures laid down in Sections 39b to 39i of the Act for determining or amending the amount and conditions of reimbursement of products in the form of liquid undivided pharmaceutical forms;
(l) the method of determining the reimbursement of products for which an application is made for the same amount of payment, irrespective of the content of the active substance in the unit of the pharmaceutical form (force),
(m) rules for determining the conditions for reimbursement in the form of prescription and indication restrictions and methods of payment;
(n) the procedure for calculating the lowest producer price in accordance with § 39c (2) (a) of the Act;
(o) details of the determination of the basic remuneration;
(p) the applicable period for assessing the availability and determination of the producer price pursuant to § 39b and 39c of the Act and the method of verifying the trade of similar products;
(q) rules for assessing the presence of the product on the market;
(r) rules for increasing and reducing the basic remuneration in the public interest;
(s) criteria for the assessment of products whose therapeutic efficacy is low, are not used for the cause of the disease, or are used for the treatment of non-serious diseases;
(t) the method of determining the usual daily therapeutic dose,
(u) the procedure for determining the basic remuneration under Paragraph 39c (5) of the Act;
(v) the basic structure of the data provided by the specialised workplace under Section 39d (4) of the Act in relation to the use of the highly innovative medicinal product and the results of this treatment;
(w) the structure of the data and the details of the documentation provided for in Article 39f (5) and (6) of the Act;
(x) the structure, method, form and time interval of the reporting pursuant to Paragraph 39zi (2) of the Act;
(y) criteria for the selection of the nearest therapeutically comparable food for special medical purposes under Section 39zg (7) (c) of the Act;
(z) the list of Member States of the European Union which publish information on food prices for special medical purposes.
Terms
For the purposes of this Order, the following definitions shall also apply:
(a) the reference product according to which the manufacturer's price is determined as the basic remuneration, the lowest foreign or Czech price of the manufacturer at the usual daily therapeutic dose;
(b) a reference indication which is common to all products included in the reference group and which depends on the determination of the basic remuneration of the reference group;
(c) the amount of the quantity of the product, expressed as the number of units of the dosage form that can be used if the product is used at the highest possible dosage, taking into account the shelf life from the first opening but not more than the actual quantity of the product,
(d) the starting dose above the usual daily therapeutic dose, divided by the number of single doses per day,
(e) the notified price the highest market price at which the marketing authorisation holder of the medicinal product, the manufacturer or the importer of a categorised food or non-authorised medicinal product used in the specific treatment programme intends to place on the market a product which is not subject to regulation of the manufacturer's price by setting a maximum price;
(f) non-serious diseases which cause only a short-term mild health disorder;
(g) the causal treatment of the disease by any therapy leading to the correction, cessation of development or mitigation of pathological processes responsible for the development of the disease, improvement of a measurable parameter, which is generally considered significant in the pathogenesis of the disease or possible complications, stabilisation of the patient's health status, or removal or mitigation of clinically significant symptoms of the disease.
RULES FOR MAXIMAL PRODUCT PRICES
DETERMINED PERIOD
Foreign exchange price conversion
(1) The prices of preparations in foreign currency are converted into Czech currency by the quarterly average of the foreign exchange market rate declared by the Czech National Bank for the calendar quarter preceding the calendar quarter in which the administrative procedure was opened (hereinafter referred to as the "operative rate").
(2) If the applicable rate differs by more than 10% from the average of the quarterly foreign exchange market rates declared by the Czech National Bank for the six calendar quarters preceding the applicable rate, and at the same time the product concerned is found to have a maximum of 3 producer prices, the price to which such difference in the applicable rate relates shall be converted into the Czech currency by the average of the foreign exchange market rate declared by the Czech National Bank for the six calendar quarters preceding the relevant rate.
(3) Each expiry of the entire 3 calendar quarters following the calendar quarter in which the administrative procedure was initiated, the State Institute for Drug Control (hereinafter referred to as the "Institute ') shall recalculate the prices of preparations in foreign currency into Czech currency, mutatis mutandis, in accordance with paragraph 1, for the preceding calendar quarter.
(4) In the case of a decision in depth or in short, a review, a decision setting a maximum price or a decision fixing the amount and conditions of payment, as well as their amendment or revocation (hereinafter referred to as "the decision '), or a judgment of the court which annulled the decision of the Constitution and returned to the case for reconsideration, the rates shall apply mutatis mutandis in accordance with paragraph 1 for the calendar quarter preceding the calendar quarter in which the renegotiation was opened.
Producer price determination
(1) The period for establishing the producer's prices is 21 days from the date of initiation of the administrative procedure.
(2) Paragraph 1 does not apply in the case of a procedure under Paragraph 39a (2) (b) of the Act; a written agreement on the highest producer price pursuant to Article 39a (2) (b) of the Act may be submitted within the time limit to comment on the supporting documents for the decision pursuant to Article 39g (5) of the Act.
(3) By the end of the entire 3 calendar quarters following the calendar quarter in which the administrative procedure was initiated, the Institute will re-establish producer prices within 21 days.
(4) In the event of a decision or judgment of the court which repeals the decision of the Constitution and the case referred back for reconsideration, the producer's prices shall be re-established within 21 days of the date of the reopening.
Assessment of availability of the product
(1) The relevant period for assessing the availability of the product is the calendar quarter preceding the calendar quarter in which the administrative procedure was opened.
(2) By the end of the entire 3 calendar quarters following the calendar quarter in which the administrative procedure was opened, the Institute will re-establish the availability of the product, for each of the preceding calendar quarters.
(3) In the event of a decision or judgment of a court which repeals the decision of the Constitution and removes the case, the availability of the product shall be re-established for the calendar quarter preceding the calendar quarter in which the renegotiation was initiated.
METHOD OF PRE-CALCULATION OF THE MAXIMAL PRICE OF THE LIKE PRODUCT
The maximum price of the product under consideration under § 39a (5) to (7) of the Act shall be determined according to the packaging of the like product under § 39b (4) of the Act with the nearest number of units of the pharmaceutical form, so that the maximum price of the like product is divided by the number of usual daily therapeutic doses in its packaging and multiplied by the number of usual daily therapeutic doses in the packaging of the product under consideration.
RULES FOR CALCULATION OF THE MAXIMAL PRICE
Exclusion of the manufacturer's foreign price
(1) If the lowest price of the product concerned found in the country of the reference basket is more than 20% lower than the average of the second and third lowest prices of the producer of that product in the other countries of the reference basket, this average or the highest price of the producer shall be used for the determination of the maximum price of the manufacturer on the basis of a written arrangement under Paragraph 39a (2) (b) of the Act, if it is lower than that average.
(2) If the Institute finds more than 3 producer prices for the product under consideration, it will not use a price to calculate the manufacturer's maximum price which is linked to the applicable rate, which differs by more than 10% from the average of the quarterly foreign exchange market rates declared by the Czech National Bank for the six calendar quarters preceding the applicable rate. Paragraph 1 shall apply mutatis mutandis.
(3) The Institute shall exclude the identified foreign price of the manufacturer in a Member State of the European Union which has taken a flat measure affecting the price of the producer of the preparation (1) if the Institute has received official information on such a flat measure from the competent authority of the Member State concerned or from the Ministry of Health.
Derogation in pack size
(1) If the product under consideration is made available on the market in the country of the reference basket only in a pack size different from that intended for the Czech market and the variation in the packaging size is not more than 10% of the unit of the pharmaceutical form, the foreign price of the manufacturer shall be converted directly into the number of units of the product under consideration for the Czech market.
(2) In case the product under assessment is not on the market in the country of the reference basket with a tolerance of 10% or more in the package size, the product may also be used in a different package size from that for the Czech market with a greater variation.
(3) Paragraph 2 shall not apply if the marketing authorisation holder of the product concerned disagrees with the application of this procedure, at the latest within the time limit to comment on the supporting documents for the decision.
ADJUSTMENT OF MAXIMAL PRICE
Increase in the maximum price in the public interest
The maximum price of the manufacturer may be increased, at the request of the party to the administrative proceedings, in the public interest provided for in Article 17 (2) of the Act, with the agreement of all health insurance companies granted at the latest within the time limit to comment on the supporting documents for the decision.
RULES FOR NOTIFICATION OF THE HIGHEST PRICE
(1) The person referred to in § 39f (2) (a) or (b) of the Act shall, after determining the amount and conditions for reimbursement of the product:
(a) by the 15th day of the month preceding the calendar quarter, an increase in the notified price at which the product will be placed on the Czech market from the calendar quarter following the notification of the price increase;
(b) by the 15th day of the preceding calendar month, the reduction of the notified price at which the product will be placed on the Czech market from the calendar month following the notification of the price reduction.
(2) The person referred to in Paragraph 39f (2) (a) or (b) of the Act may notify the price reduction referred to in paragraph 1 (b) if the product is actually placed on the Czech market in the following period.
(3) The notified price shall be deemed to be the maximum price of the product valid until the effective date of the price decision by which the product under consideration has become the unregulated maximum price of the manufacturer, unless it has been notified otherwise within the time limit referred to in paragraph 1.
RULES FOR BASIC REIMBURSEMENT
DETERMINED PERIOD
Foreign exchange price conversion
(1) Prices of preparations in foreign currency are converted into Czech currency by the quarterly average of the foreign exchange market rate announced by the Czech National Bank for the calendar quarter preceding the calendar quarter in which the administrative procedure was opened.
(2) If the applicable rate differs by more than 10% from the average of the quarterly foreign exchange market rates declared by the Czech National Bank for the six calendar quarters preceding the relevant rate, then the price to which such difference in the relevant rate relates shall be converted into the Czech currency by the average of the foreign exchange market rate declared by the Czech National Bank for the six calendar quarters preceding the relevant rate.
(3) Each end of the entire 3 calendar quarters following the calendar quarter in which the administrative procedure was opened, the Institute shall recalculate the prices of preparations in foreign currency into Czech currency, mutatis mutandis, in accordance with paragraph 1, for each previous calendar quarter.
(4) In the event of a decision or judgment of the court which repeals the decision of the Constitution and the case referred back for reconsideration, the rates shall apply mutatis mutandis in accordance with paragraph 1 for the calendar quarter preceding the calendar quarter in which the renegotiation was initiated.
Determination of producer price and exclusion of foreign producer price
(1) The period for establishing the producer's prices is 21 days from the date of initiation of the administrative procedure.
(2) In the case of a procedure under Paragraph 39c (2) (c) or (d) of the Act, paragraph 1 shall not apply; a written arrangement on the producer's highest price pursuant to § 39a (2) (b) of the Act and the remuneration agreement may be submitted within the time limit to comment on the supporting documents for the decision under § 39g (5) of the Act.
(3) By the end of the entire 3 calendar quarters following the calendar quarter in which the administrative procedure was initiated, the Institute will re-establish producer prices within 21 days.
(4) The Institute shall exclude the established foreign price of the manufacturer in a Member State of the European Union by analogy pursuant to Article 7 (3).
(5) In the event of a decision or judgment of the court which repeals the decision of the Constitution and the case referred back for reconsideration, the producer's prices shall be re-established within 21 days of the date of the reopening.
Assessment of availability of the product
(1) The relevant period for assessing the availability of the product is the calendar quarter preceding the calendar quarter in which the administrative procedure was opened.
(2) By the end of the entire 3 calendar quarters following the calendar quarter in which the administrative procedure was opened, the Institute will re-establish the availability of the product, for each of the preceding calendar quarters.
(3) In the event of a decision or judgment of a court which repeals the decision of the Constitution and removes the case, the availability of the product shall be re-established for the calendar quarter preceding the calendar quarter in which the renegotiation was initiated.
Method of verifying trade of similar product
(1) A similar product in the reference group containing the medicinal products covered by the prescription is considered to be traded on the market in the Czech Republic if the quantity of all similar products in the active substance according to § 39b (4) of the first and second sentences of the Act delivered for a given calendar month was at least 5% of the average monthly volume within all essentially therapeutically interchangeable medicinal products with the same active substance.
(2) The average monthly volume referred to in paragraph 1 shall be one twelfth of the sum of the data on the volume of deliveries over the last 12 consecutive calendar months.
(3) The Institute shall calculate the quantity referred to in paragraph 1 and the average monthly volume referred to in paragraph 2 as the number of defined daily doses in the package multiplied by the number of packages from the delivery volume reports referred to in Paragraph 77 (1) (f) of the Drug Act; If the defined daily dose is not determined, the Institute shall use the usual daily therapeutic dose and, if the usual daily therapeutic dose is not determined, the active substance shall be used in the unit of the pharmaceutical form.
(1) A similar product in a reference group containing only medicinal products paid as a separately charged medicinal product together with the relevant medical performance is considered to be traded on the market in the Czech Republic if the quantity of all similar medicinal products in the active substance according to § 39b (4) of the first and second sentences of the first and second laws supplied for the calendar month concerned was at least 2% of the average monthly volume within all essentially therapeutically interchangeable medicinal products with the same active substance.
(2) The average monthly volume referred to in paragraph 1 shall be one twelfth of the sum of the data on the volume of deliveries over the last 12 consecutive calendar months.
(3) The Institute shall calculate the quantity referred to in paragraph 1 and the average monthly volume referred to in paragraph 2 as the number of defined daily doses in the package multiplied by the number of packages from the delivery volume reports referred to in Article 33 (2) of the Medicines Act; If the defined daily dose is not determined, the Institute shall use the usual daily therapeutic dose and, if the usual daily therapeutic dose is not determined, the active substance shall be used in the unit of the pharmaceutical form.
PROCEDURE AND DETAILS FOR DETERMINING BASIC REVENUE
Calculation of basic remuneration
(1) The calculation of the basic remuneration under Paragraph 39c (2) of the Act is made by comparing the prices of the manufacturer of the strength products in the interval defined by the lower limit representing half of the starting dose and the upper limit representing twice the starting dose (hereinafter referred to as the "interval").
(2) The prices of the manufacturer of all products within the reference group belonging to the interval are divided by the number of usual daily therapeutic doses contained therein.
(3) The values obtained in calculating the basic remuneration are rounded to 8 decimal places. The basic remuneration for the usual daily therapeutic dose is rounded to 4 decimal places.
METHOD FOR DETERMINING THE DURING TERAPTIC BENEFITS
(1) The usual daily therapeutic dose is a standard maintenance dose with comparable efficacy for the normal patient in the reference indication. The usual daily therapeutic dose is expressed as the amount of active substance per day of therapy.
(2) The usual daily therapeutic dose is determined by:
(a) according to the defined daily dose recommended by the World Health Organisation, unless otherwise specified;
(b) according to the recommended dosage provided in the Summary of Product Characteristics, if different from the dosage referred to in (a),
(c) according to administrative procedures, the proven usual dosing in normal clinical practice, if different from the dosage referred to in points (a) and (b).
(3) If the product is dosed at intervals, the dose is converted to an average daily dose for the determination of the usual daily therapeutic dose. If the product is dosed based on the patient 's body weight, the dose is recalculated taking into account the average weight. If the product is dosed according to the patient' s body surface area, the dose is recalculated with respect to the ideal body surface area.
(4) If the usual daily therapeutic dose cannot be determined due to the nature of the product and the different dose ranges with regard to individual use, a single dose or, if not possible, an appropriate unit of weight of the product shall be used to determine the usual daily therapeutic dose.
(5) For products for the treatment of acute diseases, where this results from the therapeutic use and the nature of the product under consideration, when comparing the substitutability of such a product with others in the reference group, the necessary duration of treatment shall be taken into account when determining the usual daily therapeutic dose if it differs between the comparators. The resulting remuneration shall then be adjusted in the light of differences in the duration of treatment for the comparator products.
(6) The usual daily therapeutic benefit determined in accordance with paragraphs 2 to 5 in the context of the revision of payments under Paragraph 39l of the Act shall apply until the change in the subsequent in-depth revision of payments.
(7) The usual daily therapeutic dose will only be changed in the context of the revision of payments if the administrative procedure shows that the usual dosing in normal clinical practice is different from the usual daily therapeutic dose provided for in the previous revision of payments.
ADJUSTMENT OF BASIC REIMBURSEMENT
Increase in basic remuneration in the public interest
(1) In the public interest pursuant to Article 17 (2) of the Act, the Institute may, with the consent of all health insurance companies, increase the basic remuneration if the following conditions are met at the same time:
(a) they are a reference group in which products are validated by use in practice and are necessary for the provision of health care;
(b) a reference group in which products could be replaced only by more expensive products without increasing the basic remuneration in the public interest; and
(c) an increase in the basic remuneration is necessary for the product to remain on the market.
(2) In the absence of a procedure under § 39d or § 39da of the Act, the Institute may, in the public interest pursuant to § 17 (2) of the Act, increase the basic remuneration if the basic remuneration is calculated in accordance with § 39c (2) (a) of the Act and the price of the reference product is below the average of the second and third lowest prices of the reference product found in other Member States of the European Union. If the condition of the first sentence is met, the basic remuneration shall be increased to the level of the second and third lowest prices of the manufacturer of the reference product, but not more than a level ensuring the full payment of at least one product in the reference group.
(3) The Institute may not increase the basic remuneration referred to in paragraphs 1 and 2 simultaneously.
(4) The basic remuneration raised in accordance with paragraphs 1 and 2 shall not exceed the daily costs of comparable effective healthcare.
Adjustment of basic remuneration pursuant to § 39c (5) of the Act
(1) If the products in the reference group belong to the group of Annex 2 to the Act, and there is no fully paid product in this category, and the full payment of at least one product is not ensured in accordance with the procedure laid down in Paragraph 39c (2) of the Act or with an increase in this remuneration in accordance with Paragraph 16 of the reference group under consideration, then in the administrative procedure for the revision of the remuneration of the reference group under consideration, the Institute shall provide for a basic remuneration so that in the reference group under consideration the least costly product is fully covered.
(2) The least expensive product is the product with the lowest price of the manufacturer traded in the Czech Republic; Article 14 shall apply mutatis mutandis for the detection of the least expensive product.
RULES FOR PRODUCT REFUNDS
METHOD OF CALCULATION OF THE PROFIT OF THE MEDICINAL PRODUCT
Reimbursement of the starting dose and reimbursement of the products within the interval
(1) The reimbursement of the starting dose is calculated as the proportion of the basic remuneration for the usual daily therapeutic dose and the number of individual doses per day.
(2) Reimbursement per unit of dosage form of a strength different from the starting dose is calculated directly over the interval in proportion to the payment of the starting dose.
(3) The payment for packaging of the product with a force within the interval shall be calculated as the product of the payment per unit of the pharmaceutical form of the product referred to in paragraph 2 and the package size.
Reimbursement of products outside the interval
(1) The payment per unit of the dosage form at a strength below the lower interval limit is calculated using the formula
US1 = USI1 × SSI10,621488,
where US1 means payment per unit of dosage form below the lower interval limit, USI1 means payment per unit of dosage form corresponding to the lower interval, S means the force to be assessed and SI1 means the force corresponding to the lower interval.
(2) The payment per unit of dosage form above the upper limit of the interval is calculated using the formula
US2 = USI2 × SSI20,621488,
where US2 means a payment per unit of dosage form above the upper range, USI2 means a payment per unit of dosage form corresponding to the upper range, S means the assessed strength and SI2 means a force corresponding to the upper range.
(3) Non-interval preparations shall be calculated as the product of the payment per unit of pharmaceutical form referred to in paragraph 1 or 2 and the package size.
(4) In accordance with the procedure referred to in paragraph 1 or 2, the values for the strengths of the product corresponding to the lower or upper between the intervals shall be used even if the products with these forces are not traded on the market or separately covered.
(1) Paragraph 19 shall not apply and the reimbursement shall be calculated in accordance with Paragraph 18 even outside the interval for products which:
(a) are used when initiating dose titration therapy if this titration lasts for a maximum of 60 days;
(b) have an injection form where more than one unit of the formulation is to be taken for proper dosing or where the unit of the formulation can be divided into several patients; or
(c) are dosed according to body parameters.
(2) Furthermore, the procedure laid down in Sections 18 and 19 shall not apply to products not included in the reference group whose price the manufacturer is subject to regulation by setting the maximum price and is the same per unit of pharmaceutical form for all strengths of the product covered by the health insurance. In that case, the remuneration shall be set at the same level according to the strength of the reference product for all strengths of the product under consideration, so that the remuneration / price ratio of the product is constant.
(3) The procedure laid down in Sections 18 and 19 shall not apply to liquid oral preparations unless otherwise specified.
Reimbursement of similar products
The reimbursement of the product under consideration under Article 39b (5) and (6) of the Act shall be determined according to the reimbursement of a similar product under Article 39b (4) of the Act proposed by the applicant; Article 18, 19 and 20 shall apply mutatis mutandis.
REIMBURSEMENT OF TEMPORARY UNMARKS
Reimbursement of liquid oral preparations
(1) The number of starting doses in the pack shall be calculated as a proportion of the total amount of active substance in the pack and the starting dose.
(2) Reimbursement of the starting dose is calculated as a proportion of the basic remuneration and the number of individual benefits per day.
Contents
ČÁST PRVNÍ
§ 1
§ 2
ČÁST DRUHÁ
HLAVA I
§ 3
§ 4
§ 5
HLAVA II
§ 6
HLAVA III
§ 7
§ 8
HLAVA IV
§ 9
HLAVA V
§ 10
ČÁST TŘETÍ
HLAVA I
§ 11
§ 12
§ 13
§ 13a
§ 13b
HLAVA II
§ 14
HLAVA III
§ 15
HLAVA IV
§ 16
§ 17
ČÁST ČTVRTÁ
HLAVA I
§ 18
§ 19
§ 20
§ 21
HLAVA II
§ 22
§ 23
§ 24
HLAVA III
§ 25
§ 26
§ 27
§ 28
§ 29
§ 30
§ 31
HLAVA IV
§ 32
Díl 1
§ 33
§ 34
Díl 2
§ 35
§ 36
§ 37
§ 38
§ 39
ČÁST PÁTÁ
§ 42
§ 43
ČÁST ŠESTÁ
§ 45
ČÁST SEDMÁ
§ 45b
§ 45c
§ 45d
§ 45e
§ 45f
§ 45g
§ 45h
§ 45i
§ 45j
§ 45k
§ 45l
§ 45m
§ 45n
§ 45o
ČÁST OSMÁ
§ 46
§ 47
Sign in for notes, favorites and notifications
Regulation Information
| Citation | Decree No. 376 / 2011 Coll., implementing certain provisions of the Public Health Insurance Act |
|---|---|
| Regulation Type | Order |
| Author | - |
| Collection | Code of Laws |
| Date of Promulgation | 06.12.2011 |
|---|---|
| Effective from | 07.12.2011 |
| Effective until | - |
| Status | Valid |
The regulation text is for informational purposes only.
Comments 0